1. 411OInitial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. (23rd October 2018) Authors: Hilton, J; Cristea, M C; Voskoboynik, M; Postel-Vinay, S; Edenfield, W; Gavai, A; Wee, S; Srivastava, N; Klippel, A; Jackson, D; Apfel, A; Chasalow, S D; Williams, D; Donovan, M; Fischer, B; Khaldoyanidi, S; Diamond, J R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer. (1st November 2019) Authors: Allan, S; Braiteh, F; Calvo Aller, E; Cervantes, A; Edenfield, W; Li, T; Rasschaert, M; Park-Simon, T-W; Longo, F; Paz-Ares, L; Spira, A; Strauss, J; Ojalvo, LS; Helwig, C; Dussault, I; Gulley, JL Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗